Bridget K Butz1, Ting Wen1, Gerald J Gleich2, Glenn T Furuta3, Jonathan Spergel4, Eileen King5, Robert E Kramer3, Margaret H Collins6, Emily Stucke1, Colleen Mangeot5, W Daniel Jackson7, Molly O'Gorman7, J Pablo Abonia1, Scott Pentiuk8, Philip E Putnam8, Marc E Rothenberg9. 1. Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio. 2. Department of Dermatology, Department of Medicine, School of Medicine, University of Utah, Salt Lake City, Utah. 3. Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado. 4. Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 5. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio. 6. Division of Pathology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio. 7. Division of Pediatric Gastroenterology, University of Utah, Salt Lake City, Utah. 8. Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio. 9. Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio. Electronic address: rothenberg@cchmc.org.
Abstract
BACKGROUND & AIMS: We evaluated the efficacy and safety of high-dose swallowed fluticasone propionate (FP) and dose reduction in patients with eosinophilic esophagitis (EoE) and analyzed esophageal transcriptomes to identify mechanisms. METHODS: We conducted a randomized, multisite, double-blind, placebo-controlled trial of daily 1760 mcg FP in participants age 3-30 years with active EoE. Twenty-eight participants received FP, and 14 participants receivedplacebo. After 3 months, participants given FP who were in complete remission (CR) received 880 mcg FP daily, and participants in the FP or placebo groups who were not in CR continued or started, respectively, 1760 mcg FP daily for 3 additional months. The primary end point was histologic evidence for CR. Secondary end points were partial remission (PR), symptoms, compliance, esophageal gene expression, esophageal eosinophil count, and the relationship between clinical features and FP responsiveness. RESULTS: After 3 months, 65% of subjects given FP and no subjects given placebo were in CR (P = .0001); 12% of those given FP and 8% of those given placebo were in PR. In the FP group, 73% of subjects remained in CR, and 20% were in PR after the daily dose was reduced by 50%. Extending FP therapy in FP-resistant participants did not induce remission. FP decreased heartburn severity (P = .041). Compliance, age, sex, atopic status, or anthropomorphic features were not associated with response to FP. Gene expression patterns in esophageal tissues of FP responders were similar to those of patients without EoE; there was evidence for heterogeneous steroid signaling in subjects who did not respond to FP and preliminary evidence for transcripts predictive of FP responsiveness. CONCLUSIONS: Daily administration of a high dose of FP induces histologic remission in 65%-77% of patients with EoE after 3 months. A 50% dose reduction remained effective in 73%-93% of patients who initially responded to FP. Nonresponders had evidence of steroid resistance; histologic and molecular markers may predict resistance. Clinicaltrials.gov number: NCT00426283.
RCT Entities:
BACKGROUND & AIMS: We evaluated the efficacy and safety of high-dose swallowed fluticasone propionate (FP) and dose reduction in patients with eosinophilic esophagitis (EoE) and analyzed esophageal transcriptomes to identify mechanisms. METHODS: We conducted a randomized, multisite, double-blind, placebo-controlled trial of daily 1760 mcg FP in participants age 3-30 years with active EoE. Twenty-eight participants received FP, and 14 participants received placebo. After 3 months, participants given FP who were in complete remission (CR) received 880 mcg FP daily, and participants in the FP or placebo groups who were not in CR continued or started, respectively, 1760 mcg FP daily for 3 additional months. The primary end point was histologic evidence for CR. Secondary end points were partial remission (PR), symptoms, compliance, esophageal gene expression, esophageal eosinophil count, and the relationship between clinical features and FP responsiveness. RESULTS: After 3 months, 65% of subjects given FP and no subjects given placebo were in CR (P = .0001); 12% of those given FP and 8% of those given placebo were in PR. In the FP group, 73% of subjects remained in CR, and 20% were in PR after the daily dose was reduced by 50%. Extending FP therapy in FP-resistant participants did not induce remission. FP decreased heartburn severity (P = .041). Compliance, age, sex, atopic status, or anthropomorphic features were not associated with response to FP. Gene expression patterns in esophageal tissues of FP responders were similar to those of patients without EoE; there was evidence for heterogeneous steroid signaling in subjects who did not respond to FP and preliminary evidence for transcripts predictive of FP responsiveness. CONCLUSIONS: Daily administration of a high dose of FP induces histologic remission in 65%-77% of patients with EoE after 3 months. A 50% dose reduction remained effective in 73%-93% of patients who initially responded to FP. Nonresponders had evidence of steroid resistance; histologic and molecular markers may predict resistance. Clinicaltrials.gov number: NCT00426283.
Authors: W A Faubion; J Perrault; L J Burgart; N N Zein; M Clawson; D K Freese Journal: J Pediatr Gastroenterol Nutr Date: 1998-07 Impact factor: 2.839
Authors: Jonathan E Teitelbaum; Victor L Fox; Frank J Twarog; Samuel Nurko; Don Antonioli; Gerald Gleich; Kamran Badizadegan; Glenn T Furuta Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: Carine Blanchard; Ning Wang; Keith F Stringer; Anil Mishra; Patricia C Fulkerson; J Pablo Abonia; Sean C Jameson; Cassie Kirby; Michael R Konikoff; Margaret H Collins; Mitchell B Cohen; Rachel Akers; Simon P Hogan; Amal H Assa'ad; Philip E Putnam; Bruce J Aronow; Marc E Rothenberg Journal: J Clin Invest Date: 2006-02 Impact factor: 14.808
Authors: Michael R Konikoff; Richard J Noel; Carine Blanchard; Cassie Kirby; Sean C Jameson; Bridget K Buckmeier; Rachel Akers; Mitchell B Cohen; Margaret H Collins; Amal H Assa'ad; Seema S Aceves; Philip E Putnam; Marc E Rothenberg Journal: Gastroenterology Date: 2006-08-16 Impact factor: 22.682
Authors: Glenn T Furuta; Chris A Liacouras; Margaret H Collins; Sandeep K Gupta; Chris Justinich; Phil E Putnam; Peter Bonis; Eric Hassall; Alex Straumann; Marc E Rothenberg Journal: Gastroenterology Date: 2007-08-08 Impact factor: 22.682
Authors: Richard J Noel; Philip E Putnam; Margaret H Collins; Amal H Assa'ad; Jesus R Guajardo; Sean C Jameson; Marc E Rothenberg Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382
Authors: Elizabeth T Jensen; Kevin Z Huang; Hannah X Chen; Lisa E Landes; Kristen A McConnell; Mary Angie Almond; Anca M Safta; Douglas T Johnston; Raquel Durban; Laura Jobe; Carrie Frost; Sarah Donnelly; Brady Antonio; Antonio Quiros; Jonathan E Markowitz; Evan S Dellon Journal: J Pediatr Gastroenterol Nutr Date: 2019-01 Impact factor: 2.839
Authors: E S Dellon; L L Higgins; R Beitia; S Rusin; J T Woosley; R Veerappan; S R Selitsky; J S Parker; R M Genta; R H Lash; R Aranda; R J Peach; M Grimm Journal: Aliment Pharmacol Ther Date: 2016-05-18 Impact factor: 8.171
Authors: Cary C Cotton; Daniel Erim; Swathi Eluri; Sarah H Palmer; Daniel J Green; W Asher Wolf; Thomas M Runge; Stephanie Wheeler; Nicholas J Shaheen; Evan S Dellon Journal: Clin Gastroenterol Hepatol Date: 2016-12-07 Impact factor: 11.382